Federated Hermes’s GenMark Diagnostics, Inc GNMK Stock Holding History

Federated Hermes’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-200,000	Closed	-$1.3M	–	2328
2019 Q2	$1.3M	Hold	200,000	–	–	﹤0.01%	1216
2019 Q1	$1.42M	Hold	200,000	–	–	﹤0.01%	1186
2018 Q4	$972K	Hold	200,000	–	–	﹤0.01%	1297
2018 Q3	$1.47M	Hold	200,000	–	–	﹤0.01%	1222
2018 Q2	$1.28M	Hold	200,000	–	–	﹤0.01%	1203
2018 Q1	$1.09M	Hold	200,000	–	–	﹤0.01%	1203
2017 Q4	$834K	Hold	200,000	–	–	﹤0.01%	1271
2017 Q3	$1.93M	Hold	200,000	–	–	0.01%	937
2017 Q2	$2.37M	Buy	200,000 +199,683	+62,991%	+$2.55M	0.01%	834
2017 Q1	$4K	Buy	+317	New	+$3.82K	﹤0.01%	1984

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Federated Hermes's GNMK Position: Q3 2019 in Review

Federated Hermes sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2019, closing a stake of 200,000 shares — an estimated $1.3M sold.

Federated Hermes first reported a position in GNMK in Q1 2017 and held it in 10 quarters. The position peaked at $2.37M in Q2 2017. 110 funds tracked by Wall St. Rank hold GNMK as of Q3 2019.

Federated Hermes reported no remaining GenMark Diagnostics, Inc position as of Q3 2019 after selling out during the quarter.
Federated Hermes sold 200,000 GenMark Diagnostics, Inc shares in Q3 2019, an estimated $1.3M.
Federated Hermes first reported a position in GenMark Diagnostics, Inc in Q1 2017 and held it in 10 quarters.
Federated Hermes's GenMark Diagnostics, Inc position peaked at $2.37M in Q2 2017.
110 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2019.

Based on Federated Hermes's 13F filing for Q3 2019, filed 14 Nov 2019.